Defining prognostic parameters of well-differentiated gastric neuroendocrine tumors based on metastatic potential: a two-center experience

被引:5
|
作者
Kurtulan, O. [1 ]
Turhan, N. [2 ]
Gedikoglu, G. [1 ]
Akyol, A. [1 ]
Sokmensuer, C. [1 ]
机构
[1] Hacettepe Univ, Fac Med, Dept Pathol, Ankara, Turkey
[2] Univ Hlth Sci, Ankara City Hosp, Dept Pathol, Ankara, Turkey
关键词
gastric neuroendocrine tumors; grade; clinicopathologic classification; prognosis; CARCINOID-TUMORS; TYPE-1; EPIDEMIOLOGY; MANAGEMENT; NEOPLASIA;
D O I
10.51821/85.2.8601
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Gastric neuroendocrine tumors [gNETs] are heterogeneous tumors and we are still unable to predict the behavior of these tumors. We aim to define the prognostic parameters of well-differentiated gNETs based on metastatic potential and to evaluate the current classification systems. Patients and methods: We retrospectively retrieved 44 well differentiated gNET cases who underwent radical surgery between 2000-2015 at two tertiary-care centers. Results: Among the 44 well-differentiated gNET patients, 17 (38%) patients had metastatic disease to lymph nodes and/or distant sites, while 27 (62%) were confined to the stomach. Higher risk of metastasis was observed with increasing tumor size, grade, depth of invasion and with type-3 and solitary tumors. 30 (68%) patients had type-1 gNET and 14 (32%) had type-3 gNET. Majority of the type-1 cases (76,6%) were Grade 1 [G1] and type-3 cases (78,5%) were Grade 3 [G3]. Type-1 subgroup had no G3 tumor, and type-3 had no G1. Grade 2 [G2] tumors were more controversial, with metastatic and non-metastatic cases. G2 cases with a >10% Ki67 expression or type-3, had a worse prognosis. Although most of the type-1 gNETs had an indolent course, 6 of 30 (20%) patients had metastatic disease. Metastasizing type-1 gNETs were >10 mm in diameter or extended to/beyond the submucosa. Conclusion: Regarding our results, tumor type, grade, size, focality and depth of invasion are the prognostic parameters for gNETs, based on metastatic potential. Besides these parameters, a two-tiered grading system with a 10% Ki-67 proliferation index cut-off value could be considered for right treatment choice. (Acta gastroenterol. belg., 2022, 85, 339-345).
引用
收藏
页码:339 / 345
页数:7
相关论文
共 50 条
  • [31] Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan
    Taku Aoki
    Norihiro Kokudo
    Izumi Komoto
    Kyoichi Takaori
    Wataru Kimura
    Keiji Sano
    Takeshi Takamoto
    Takuya Hashimoto
    Takuji Okusaka
    Chigusa Morizane
    Tetsuhide Ito
    Masayuki Imamura
    Journal of Gastroenterology, 2015, 50 : 769 - 775
  • [32] Efficacy of Capecitabine and Temozolomide Combination in Well-Differentiated Neuroendocrine Tumors Jordan Experience
    Abbasi, Salah
    Kashashna, Amneh
    Albaba, Hamzeh
    PANCREAS, 2014, 43 (08) : 1303 - 1305
  • [33] Appendiceal Well-Differentiated Neuroendocrine Tumors: A Single-Center Experience and New Insights into the Effective Use of Immunohistochemistry
    Shibahara, Yukiko
    Krzyzanowska, Monika
    Vajpeyi, Rajkumar
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2023, 31 (03) : 252 - 259
  • [34] An unexpected effect of chronic treatment with Temozolomide in patients with metastatic, well-differentiated neuroendocrine tumors
    Laffi, A.
    Nicosia, L.
    Spada, F.
    Rubino, M.
    Fazio, N.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 138 - 138
  • [35] Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors
    P. Jiménez-Fonseca
    A. Carmona-Bayonas
    E. Martín-Pérez
    G. Crespo
    R. Serrano
    M. Llanos
    C. Villabona
    R. García-Carbonero
    J. Aller
    J. Capdevila
    E. Grande
    Cancer and Metastasis Reviews, 2015, 34 : 381 - 400
  • [36] Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.
    Dogan, Izzet
    Tastekin, Didem
    Karabulut, Senem
    Sakar, Burak
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [37] Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors
    Jimenez-Fonseca, P.
    Carmona-Bayonas, A.
    Martin-Perez, E.
    Crespo, G.
    Serrano, R.
    Llanos, M.
    Villabona, C.
    Garcia-Carbonero, R.
    Aller, J.
    Capdevila, J.
    Grande, E.
    CANCER AND METASTASIS REVIEWS, 2015, 34 (03) : 381 - 400
  • [38] Outcomes of Cytoreductive Surgery for Well-Differentiated Metastatic Neuroendocrine Tumors in the Setting of Extrahepatic Metastases
    Hallet, J.
    Koudjanian, S.
    Beyfuss, K.
    Coburn, N.
    Karanicolas, P.
    Singh, S.
    Law, C.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S96 - S97
  • [39] Relevance of Serum Chromogranin A as Diagnostic and Prognostic Marker for Well-Differentiated Pancreatic Neuroendocrine Tumors
    Pulvirenti, Alessandra
    Rao, Deepthi
    Tang, Laura
    Gonen, Mithat
    Fleisher, Martin
    Reidy-Lagunes, Diane
    Allen, Peter
    PANCREAS, 2018, 47 (03) : 352 - 353
  • [40] Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors
    Lamberti, G.
    Ceccarelli, C.
    Brighi, N.
    Maggio, I.
    Santini, D.
    Mosconi, C.
    Ricci, C.
    Biasco, G.
    Campana, D.
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2017, 2017